Illumina vs Tempus AI, Inc. Class A Common Stock: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Illumina Inc (ILMN)

Q3 202624 Jun – 7 Sep 2026

▲2▼1

Illumina Surges on Earnings Beat, S&P 500 Entry, Biotech Boom

Earnings Beat and Raised Guidance Illumina beat earnings and raised guidance, with revenue up 4.8% to $1.09 billion. Clinical sequencing demand stayed strong, growing 20% outside China, and NovaSeq X placements topped 80 units.
This point explains the fundamental business strength that drove the stock higher.
S&P 500 Inclusion and Biotech Boom The stock gained 46% amid a biotech boom, and Illumina joined the S&P 500, attracting index-fund demand. Eli Lilly joined its Billion Cell Atlas, and Merck/Moderna's cancer vaccine success boosted shares 15.6%.
This point captures the market and partnership catalysts that amplified the stock's rise.
Roche Launches Cheaper Competing Sequencer Roche launched a competing sequencer at $750,000, well below Illumina's $985,000–$1.25 million, threatening its ~70% market share and potentially forcing price cuts or slower sales. Analysts expect gradual share erosion rather than collapse.
This point highlights the main competitive threat that could pressure future growth.

August 202620 Jul – 7 Sep 2026

▲4

Illumina lifts outlook, joins S&P 500, and gains AI drug-discovery partners

Raised 2026 revenue guidance on clinical sequencing demand Illumina lifted its full-year 2026 revenue outlook to $4.60–$4.64 billion, up from the prior range, as clinical sequencing and consumables demand ran stronger than expected. That tells investors the core business is growing faster than previously thought, which supports a higher stock price.
This is the single biggest new fundamental driver of the period, directly raising the company's own sales forecast.
Eli Lilly joins Illumina's Billion Cell Atlas Eli Lilly became a founding member of Illumina's Billion Cell Atlas, a huge map of how genes behave in disease. Lilly and other drugmakers pay to use Illumina's sequencing and data, so more partners mean more recurring demand for Illumina's machines and services.
It is a new commercial partnership that expands demand for Illumina's platform and validates its data strategy.
Cancer vaccine success boosts demand for Illumina sequencers Merck and Moderna's positive Phase 3 cancer vaccine results lifted Illumina shares 15.6% because every personalized cancer vaccine dose requires Illumina's NovaSeq X sequencers. If this new class of treatments wins approval, it creates a large, recurring need for Illumina's machines and consumables.
It shows a new end-market — personalized cancer vaccines — that could become a major source of future demand for Illumina.
Illumina to join the S&P 500 index Illumina will move from the S&P 400 into the S&P 500 on September 21. Index funds that track the S&P 500 must buy the stock, creating automatic demand. It also raises Illumina's profile among large investors, which can support the share price over time.
It is a new capital-markets event that mechanically increases demand for ILMN shares.

Latest20 Jul – 7 Sep 2026

▲4

Illumina lifts outlook, joins S&P 500, and gains AI drug-discovery partners

Raised 2026 revenue guidance on clinical sequencing demand Illumina lifted its full-year 2026 revenue outlook to $4.60–$4.64 billion, up from the prior range, as clinical sequencing and consumables demand ran stronger than expected. That tells investors the core business is growing faster than previously thought, which supports a higher stock price.
This is the single biggest new fundamental driver of the period, directly raising the company's own sales forecast.
Eli Lilly joins Illumina's Billion Cell Atlas Eli Lilly became a founding member of Illumina's Billion Cell Atlas, a huge map of how genes behave in disease. Lilly and other drugmakers pay to use Illumina's sequencing and data, so more partners mean more recurring demand for Illumina's machines and services.
It is a new commercial partnership that expands demand for Illumina's platform and validates its data strategy.
Cancer vaccine success boosts demand for Illumina sequencers Merck and Moderna's positive Phase 3 cancer vaccine results lifted Illumina shares 15.6% because every personalized cancer vaccine dose requires Illumina's NovaSeq X sequencers. If this new class of treatments wins approval, it creates a large, recurring need for Illumina's machines and consumables.
It shows a new end-market — personalized cancer vaccines — that could become a major source of future demand for Illumina.
Illumina to join the S&P 500 index Illumina will move from the S&P 400 into the S&P 500 on September 21. Index funds that track the S&P 500 must buy the stock, creating automatic demand. It also raises Illumina's profile among large investors, which can support the share price over time.
It is a new capital-markets event that mechanically increases demand for ILMN shares.

July 202624 Jun – 9 Jul 2026

▲3▼1

Illumina beats earnings, raises guidance, but Roche undercuts with cheaper sequencer

Earnings beat and raised guidance Illumina reported quarterly revenue of $1.09 billion, up 4.8% from a year ago, and raised its full-year profit guidance above what analysts expected. This shows the company is growing and more profitable than thought, which pushes the stock up because investors pay more for a business that earns more.
This is the biggest new positive event this period and directly explains the stock's jump.
Roche launches cheaper competing sequencer Roche launched a gene sequencing machine priced at $750,000, well below Illumina's NovaSeq X at $985,000 to $1.25 million. This threatens Illumina's roughly 70% market share and could force price cuts or slow sales, weighing on the stock. Analysts expect a gradual share shift, not a sudden collapse.
This is a new competitive threat that directly pressures Illumina's pricing and market dominance.
Clinical sequencing demand stays strong Clinical sequencing consumables demand outside China rose 20% for the second straight quarter, and NovaSeq X placements topped 80 units. Clinical tests now make up over 60% of sequencing consumables, giving Illumina recurring revenue and better long-term earnings visibility, which supports a higher stock price.
This shows the underlying demand driving Illumina's growth is durable, a key reason the stock has surged.
Biotech sector boom lifts Illumina The biotech sector is hitting new highs as the AI trade cools, and Illumina has gained about 46% this year. A stronger drug development cycle and renewed investor interest in biotech pull money into the sector, lifting Illumina's stock along with it. This is a broad tailwind, not company-specific.
This explains the sector-wide force behind Illumina's rally, giving the big-picture context.

24 Jun – 9 Jul 2026

▲3▼1

Illumina beats earnings, raises guidance, but Roche undercuts with cheaper sequencer

Earnings beat and raised guidance Illumina reported quarterly revenue of $1.09 billion, up 4.8% from a year ago, and raised its full-year profit guidance above what analysts expected. This shows the company is growing and more profitable than thought, which pushes the stock up because investors pay more for a business that earns more.
This is the biggest new positive event this period and directly explains the stock's jump.
Roche launches cheaper competing sequencer Roche launched a gene sequencing machine priced at $750,000, well below Illumina's NovaSeq X at $985,000 to $1.25 million. This threatens Illumina's roughly 70% market share and could force price cuts or slow sales, weighing on the stock. Analysts expect a gradual share shift, not a sudden collapse.
This is a new competitive threat that directly pressures Illumina's pricing and market dominance.
Clinical sequencing demand stays strong Clinical sequencing consumables demand outside China rose 20% for the second straight quarter, and NovaSeq X placements topped 80 units. Clinical tests now make up over 60% of sequencing consumables, giving Illumina recurring revenue and better long-term earnings visibility, which supports a higher stock price.
This shows the underlying demand driving Illumina's growth is durable, a key reason the stock has surged.
Biotech sector boom lifts Illumina The biotech sector is hitting new highs as the AI trade cools, and Illumina has gained about 46% this year. A stronger drug development cycle and renewed investor interest in biotech pull money into the sector, lifting Illumina's stock along with it. This is a broad tailwind, not company-specific.
This explains the sector-wide force behind Illumina's rally, giving the big-picture context.

Tempus AI, Inc. Class A Common Stock (TEM)

Q3 202618 Jun – 11 Sep 2026

▲4

Tempus swings to profit, raises outlook, expands cancer data reach

Q2 profit and raised 2026 revenue guidance Tempus reported Q2 2026 net income of $5.64 million, a swing from a $42.84 million loss a year earlier, and lifted full-year revenue guidance to $1.60–$1.61 billion. Turning profitable and raising the outlook supports the growth story and helps justify a higher stock price.
This is the period's clearest fundamental shift, directly improving earnings and forward revenue expectations.
Personalis acquisition deepens cancer recurrence testing Tempus agreed to buy Personalis for $16.25 per share, a $1.5 billion enterprise value, adding minimal residual disease testing to its oncology platform. The deal expands its cancer genomics and data offerings, though the initial market reaction was slightly negative on cost concerns.
The acquisition is a major strategic move that broadens Tempus's technology and data moat, affecting long-term growth.
mRNA melanoma trial win lifts oncology data demand A phase 3 trial showed a customized mRNA melanoma treatment improved recurrence-free survival, sending Tempus shares up 39.5%. The result highlights how Tempus's data and AI tools are embedded in cutting-edge oncology, potentially boosting demand for its data and testing services.
This event directly drove a large price move and validates Tempus's role in advanced cancer research.
100,000-genome dataset expands AI research platform Tempus launched an initiative to build a 100,000 whole-genome dataset linked to clinical outcomes, with a long-term goal of one million genomes. This expands its data platform for AI-driven research, strengthening its competitive position and future data revenue potential.
The new dataset initiative is a fresh expansion of Tempus's core data asset, supporting long-term growth.

July 202618 Jun – 11 Sep 2026

▲4

Tempus swings to profit, raises outlook, expands cancer data reach

Q2 profit and raised 2026 revenue guidance Tempus reported Q2 2026 net income of $5.64 million, a swing from a $42.84 million loss a year earlier, and lifted full-year revenue guidance to $1.60–$1.61 billion. Turning profitable and raising the outlook supports the growth story and helps justify a higher stock price.
This is the period's clearest fundamental shift, directly improving earnings and forward revenue expectations.
Personalis acquisition deepens cancer recurrence testing Tempus agreed to buy Personalis for $16.25 per share, a $1.5 billion enterprise value, adding minimal residual disease testing to its oncology platform. The deal expands its cancer genomics and data offerings, though the initial market reaction was slightly negative on cost concerns.
The acquisition is a major strategic move that broadens Tempus's technology and data moat, affecting long-term growth.
mRNA melanoma trial win lifts oncology data demand A phase 3 trial showed a customized mRNA melanoma treatment improved recurrence-free survival, sending Tempus shares up 39.5%. The result highlights how Tempus's data and AI tools are embedded in cutting-edge oncology, potentially boosting demand for its data and testing services.
This event directly drove a large price move and validates Tempus's role in advanced cancer research.
100,000-genome dataset expands AI research platform Tempus launched an initiative to build a 100,000 whole-genome dataset linked to clinical outcomes, with a long-term goal of one million genomes. This expands its data platform for AI-driven research, strengthening its competitive position and future data revenue potential.
The new dataset initiative is a fresh expansion of Tempus's core data asset, supporting long-term growth.

Latest18 Jun – 11 Sep 2026

▲4

Tempus swings to profit, raises outlook, expands cancer data reach

Q2 profit and raised 2026 revenue guidance Tempus reported Q2 2026 net income of $5.64 million, a swing from a $42.84 million loss a year earlier, and lifted full-year revenue guidance to $1.60–$1.61 billion. Turning profitable and raising the outlook supports the growth story and helps justify a higher stock price.
This is the period's clearest fundamental shift, directly improving earnings and forward revenue expectations.
Personalis acquisition deepens cancer recurrence testing Tempus agreed to buy Personalis for $16.25 per share, a $1.5 billion enterprise value, adding minimal residual disease testing to its oncology platform. The deal expands its cancer genomics and data offerings, though the initial market reaction was slightly negative on cost concerns.
The acquisition is a major strategic move that broadens Tempus's technology and data moat, affecting long-term growth.
mRNA melanoma trial win lifts oncology data demand A phase 3 trial showed a customized mRNA melanoma treatment improved recurrence-free survival, sending Tempus shares up 39.5%. The result highlights how Tempus's data and AI tools are embedded in cutting-edge oncology, potentially boosting demand for its data and testing services.
This event directly drove a large price move and validates Tempus's role in advanced cancer research.
100,000-genome dataset expands AI research platform Tempus launched an initiative to build a 100,000 whole-genome dataset linked to clinical outcomes, with a long-term goal of one million genomes. This expands its data platform for AI-driven research, strengthening its competitive position and future data revenue potential.
The new dataset initiative is a fresh expansion of Tempus's core data asset, supporting long-term growth.